Impact of Acute Phase Epigallocatechin-3-gallate Supplementation on Consciousness and S100B Serum Levels in TBI Patients: A Double Blind Randomized Clinical Trial | Zendy

Leila Zareian | Zendy; Amir Azarhomayoun | Zendy; Maysam Alimohamadi | Zendy; Mohammadreza Khajavi | Zendy; Soodeh Razeghi-Jahromi | Zendy

Open Access

Impact of Acute Phase Epigallocatechin-3-gallate Supplementation on Consciousness and S100B Serum Levels in TBI Patients: A Double Blind Randomized Clinical Trial

Author(s) -

Leila Zareian,

Amir Azarhomayoun,

Maysam Alimohamadi,

Mohammadreza Khajavi,

Soodeh Razeghi-Jahromi

Publication year - 2017

Publication title -

iranian journal of neurosurgery

Language(s) - English

Resource type - Journals

eISSN - 2423-6829

pISSN - 2423-6497

DOI - 10.29252/irjns.3.2.51

Subject(s) - randomized controlled trial , medicine , double blind , clinical trial , gallate , consciousness , epigallocatechin gallate , traumatic brain injury , psychology , pharmacology , alternative medicine , psychiatry , antioxidant , pathology , biology , polyphenol , biochemistry , placebo , neuroscience

Background and Aim: Traumatic brain injury is one of the leading causes of mortality and disability in young adults. Epigallocatechin-3-gallate, the antioxidant compound of green tea, has been proposed to have antioxidant and anti-inflammatory properties. This study evaluates the potential effects of epigallocatechin-3-gallate on the early clinical outcome and serum S100B levels (biomarker for brain tissue damage severity) in patients with moderate to severe traumatic brain injury.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research